5 results
Primary ObjectiveThe primary objective of this study is to evaluate the effect of 12 weeks of treatment with 2 different doses of oral AQX-1125 (100 mg or 200 mg) administered once daily compared to placebo on the change from Baseline (Visit 2) to…
To determine the influence of darolutamide on the pharmacokinetics of cabazitaxel compared to cabazitaxel alone in mCRPC patients.
Primary objective To investigate the safety and tolerability of CCS1477 as monotherapy and in combination.
The aim of this study is to determine whether the alleged positive effects of ESG on acute surgical wounds as well as ESG effects on chronic wounds are attributable to this intervention.
To compare progression free survival (PFS) between treatment with docetaxel or cabazitaxel and darolutamide versus treatment with docetaxel or cabazitaxel in mCRPC patients.